Commvault Systems Inc vs Exelixis Inc. Common Stock — how do they compare? Commvault Systems Inc trades at $152.48 (market cap $6.25B), while Exelixis Inc. Common Stock trades at $59.7 (market cap $14.62B). The key difference: Exelixis Inc. Common Stock is far larger — about 2.3× Commvault Systems Inc's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Exelixis Inc. Common Stock for 0 Days on average.
| CVLT | EXEL | |
|---|---|---|
Market Cap | $6.25B | $14.62B |
Volume | 632,727 | 2,684,957 |
Sector | Technology | Health |
52-Week High | $176.52 | $59.13 |
52-Week Low | $75.18 | $34.54 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $6.24B | $13.95B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.74, up 0.31% with strong bullish technical momentum. The stock shows robust earnings performance, beating estimates for three consecutive quarters, with Q3 2026 results pending. Recent business developments include AWS Data Competency achievement and expanded FedRAMP authorization, positioning the company for growth in AI-driven resilience markets.
The outlook remains positive with 54.5% analyst buy ratings and a $156.55 consensus target, though high valuation multiples and declining profit margins warrant caution. Key risks include competitive pressures in cybersecurity and execution challenges in maintaining growth momentum amid expanding AI capabilities.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →